Autoantibodies Enhance Agonist Action and Binding to Cardiac Muscarinic Receptors in Chronic Chagas' Disease

REFERENCES

• Schmunis G A. American Tripanosomiasis as a public health problem. Chagas' Disease and the Nervous System. Pan-American Health Organization, Washington, DC 1994; 3–31, Scientific publication 547
   Google Scholar
• Calabrese F, Thiene G. Myocarditis and inflammatory cardiomyopathy: Microbiological and molecular biological aspects. Cardiovasc Res 2003; 60: 11–25
   PubMed Web of Science ®Google Scholar
• Mason J W. Myocarditis and dilated cardiomyopathy: An inflammatory link. Cardiovasc Res 2003; 60: 5–10
   PubMed Web of Science ®Google Scholar
• Chiale P A, Ferrari I, Mahler E, Vallazza M A, Elizari M V, Rosenbaum M B, et al. Differential profile and biochemical effects of antiautonomic membrane receptor antibodies in ventricular arrhythmias and sinus node dysfunction. Circulation 2001; 103: 1765–1771
   PubMed Web of Science ®Google Scholar
• Matsui S, Fu M L. Myocardial injury due to G-protein coupled receptor-autoimmunity. Jpn Heart J 1998; 39: 261–274
   PubMedGoogle Scholar
• Kierszenbaum F. Views on the autoimmunity hypothesis for Chagas disease pathogenesis. FEMS Immunol Med Microbiol 2003; 37: 1–11
   Google Scholar
• Gimenez L E, Hernandez C C, Mattos E C, Brandao I T, Olivieri B, Campelo R P, et al. DNA immunizations with M2 muscarinic and β1 adrenergic receptor coding plasmids impair cardiac function in mice. J Mol Cell Cardiol 2005; 38: 703–714
   PubMed Web of Science ®Google Scholar
• Hernandez C C, Barcellos L C, Gimenez L E, Cabarcas R A, Garcia S, Pedrosa R C, et al. Human chagasic IgGs bind to cardiac muscarinic receptors and impair L-type Ca2 + currents. Cardiovasc Res 2003; 58: 55–65
   PubMed Web of Science ®Google Scholar
• Elies R, Ferrari I, Wallukat G, Lebesgue D, Chiale P, Elizari M, et al. Structural and functional analysis of the B cell epitopes recognized by anti-receptor autoantibodies in patients with Chagas' disease. J Immunol 1996; 157: 4203–4211
   PubMed Web of Science ®Google Scholar
• Ferrari I, Levin M J, Wallukat G, Elies R, Lebesgue D, Chiale P, et al. Molecular mimicry between the immunodominant ribosomal protein P0 of Trypanosoma cruzi and a functional epitope on the human beta 1-adrenergic receptor. J Exp Med 1995; 182: 59–65
   PubMed Web of Science ®Google Scholar
• Christopoulos A, Lanzafame A, Mitchelson F. Allosteric interactions at muscarinic cholinoceptors. Clin Exp Pharmacol Physiol 1998; 25: 185–194
   PubMedGoogle Scholar
• Leppik R A, Miller R C, Eck M, Paquet J L. Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. Mol Pharmacol 1994; 45: 983–990
   Google Scholar
• Lazareno S, Birdsall N J. Detection, quantitation, and verification of allosteric interactions of agents with labeled and unlabeled ligands at G protein-coupled receptors: Interactions of strychnine and acetylcholine at muscarinic receptors. Mol Pharmacol 1995; 48: 362–378
   PubMed Web of Science ®Google Scholar
• Trankle C, Mohr K. Divergent modes of action among cationic allosteric modulators of muscarinic M2 receptors. Mol Pharmacol 1997; 51: 674–682
   Google Scholar
• Espinosa R, Carrasco H A, Belandria F, Fuenmayor A M, Molina C, Gonzalez R, et al. Life expectancy analysis in patients with Chagas' disease: prognosis after one decade (1973–1983). Int J Cardiol 1985; 8: 45–56
   PubMed Web of Science ®Google Scholar
• de Oliveira S F, Pedrosa R C, Nascimento J H, Campos de Carvalho A C, Masuda M O. Sera from chronic chagasic patients with complex cardiac arrhythmias depress electrogenesis and conduction in isolated rabbit hearts. Circulation 1997; 96: 2031–2037
   PubMedGoogle Scholar
• Costa P C, Fortes F S, Machado A B, Almeida N A, Olivares E L, Cabral P R, et al. Sera from chronic chagasic patients depress cardiac electrogenesis and conduction. Braz J Med Biol Res 2000; 33: 439–446
   PubMed Web of Science ®Google Scholar
• World Medical Association. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. Bull World Health Organ 2001; 79: 373–374
   PubMed Web of Science ®Google Scholar
• Lowry O H, Rosebrough N J, Farr A L, Randall R J. Protein measurement with the Folin phenol reagent. J Biol Chem 1951; 193: 265–275
   PubMed Web of Science ®Google Scholar
• World Medical Association, American Physiological Society. Guiding principles for research involving animals and human beings. Am J Physiol Regul Integr Comp Physiol 2002; 283: R281–283
   Google Scholar
• Lazareno S, Birdsall N. Measurement of competitive and allosteric interactions in radioligand binding studies. G Protein-Coupled Receptors, T Haga, G Berstein. CRC Press, Boca Raton 1999; 1–48
   Google Scholar
• Lew M J, Angus J A. Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 1995; 16: 328–337
   PubMed Web of Science ®Google Scholar
• Clark A L, Mitchelson F. The inhibitory effect of gallamine on muscarinic receptors. Br J Pharmacol 1976; 58: 323–331
   PubMed Web of Science ®Google Scholar
• Lee N H, el-Fakahany E E. Allosteric antagonists of the muscarinic acetylcholine receptor. Biochem Pharmacol 1991; 42: 199–205
   PubMed Web of Science ®Google Scholar
• Ellis J, Huyler J, Brann M R. Allosteric regulation of cloned m1-m5 muscarinic receptor subtypes. Biochem Pharmacol 1991; 42: 1927–1932
   Google Scholar
• Trankle C, Kostenis E, Burgmer U, Mohr K. Search for lead structures to develop new allosteric modulators of muscarinic receptors. J Pharmacol Exp Ther 1996; 279: 926–933
   PubMedGoogle Scholar
• Burgmer U, Schulz U, Trankle C, Mohr K. Interaction of Mg2 + with the allosteric site of muscarinic M2 receptors. Naunyn Schmiedebergs Arch Pharmacol 1998; 357: 363–370
   Google Scholar
• Goin J C, Borda E, Leiros C P, Storino R, Sterin-Borda L. Identification of antibodies with muscarinic cholinergic activity in human Chagas' disease: pathological implications. J Auton Nerv Syst 1994; 47: 45–52
   Google Scholar
• Goin J C, Leiros C P, Borda E, Sterin-Borda L. Interaction of human chagasic IgG with the second extracellular loop of the human heart muscarinic acetylcholine receptor: Functional and pathological implications. FASEB J 1997; 11: 77–83
   PubMed Web of Science ®Google Scholar
• Masuda M O, Levin M, De Oliveira S F, Dos Santos Costa P C, Bergami P L, Dos Santos Almeida N A, et al. Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens. FASEB J 1998; 12: 1551–1558
   Google Scholar
• Wallukat G, Nissen E, Morwinski R, Muller J. Autoantibodies against the beta- and muscarinic receptors in cardiomyopathy. Herz 2000; 25: 261–266
   PubMed Web of Science ®Google Scholar
• Goin J C, Borda E S, Auger S, Storino R, Sterin-Borda L. Cardiac M(2) muscarinic cholinoceptor activation by human chagasic autoantibodies: Association with bradycardia. Heart 1999; 82: 273–278
   Google Scholar
• Sterin-Borda L, Joensen L, Bayo-Hanza C, Esteva M, Borda E. Therapeutic use of muscarinic acetylcholine receptor peptide to prevent mice chagasic cardiac dysfunction. J Mol Cell Cardiol 2002; 34: 1645–1654
   PubMed Web of Science ®Google Scholar
• Sterin-Borda L, Gorelik G, Borda E S. Chagasic IgG binding with cardiac muscarinic cholinergic receptors modifies cholinergic-mediated cellular transmembrane signals. Clin Immunol Immunopathol 1991; 61: 387–397
   Google Scholar
• Gether U. Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. Endocr Rev 2000; 21: 90–113
   PubMed Web of Science ®Google Scholar
• Mirzadegan T, Benko G, Filipek S, Palczewski K. Sequence analyses of G-protein-coupled receptors: Similarities to rhodopsin. Biochemistry 2003; 42: 2759–2767
   PubMed Web of Science ®Google Scholar
• Fraser C M, Wang C D, Robinson D A, Gocayne J D, Venter J C. Site-directed mutagenesis of m1 muscarinic acetylcholine receptors: conserved aspartic acids play important roles in receptor function. Mol Pharmacol 1989; 36: 840–847
   PubMedGoogle Scholar
• Page K M, Curtis C A, Jones P G, Hulme E C. The functional role of the binding site aspartate in muscarinic acetylcholine receptors, probed by site-directed mutagenesis. Eur J Pharmacol 1995; 289: 429–437
   PubMedGoogle Scholar
• Hulme E C, Lu Z L, Saldanha J W, Bee M S. Structure and activation of muscarinic acetylcholine receptors. Biochem Soc Trans 2003; 31: 29–34
   Google Scholar
• Vogel W K, Sheehan D M, Schimerlik M I. Site-directed mutagenesis on the m2 muscarinic acetylcholine receptor: The significance of Tyr403 in the binding of agonists and functional coupling. Mol Pharmacol 1997; 52: 1087–1094
   Google Scholar
• Stockton J M, Birdsall N J, Burgen A S, Hulme E C. Modification of the binding properties of muscarinic receptors by gallamine. Mol Pharmacol 1983; 23: 551–557
   PubMed Web of Science ®Google Scholar
• Proska J, Tucek S. Mechanisms of steric and cooperative actions of alcuronium on cardiac muscarinic acetylcholine receptors. Mol Pharmacol 1994; 45: 709–717
   Google Scholar
• Krejci A, Tucek S. Changes of cooperativity between N-methylscopolamine and allosteric modulators alcuronium and gallamine induced by mutations of external loops of muscarinic M(3) receptors. Mol Pharmacol 2001; 60: 761–767
   Google Scholar
• Elies R, Fu L X, Eftekhari P, Wallukat G, Schulze W, Granier C, et al. Immunochemical and functional characterization of an agonist-like monoclonal antibody against the M2 acetylcholine receptor. Eur J Biochem 1998; 251: 659–666
   PubMedGoogle Scholar
• Ellis J, Seidenberg M. Two allosteric modulators interact at a common site on cardiac muscarinic receptors. Mol Pharmacol 1992; 42: 638–641
   PubMed Web of Science ®Google Scholar
• Lanzafame A, Christopoulos A, Mitchelson F. Three allosteric modulators act at a common site, distinct from that of competitive antagonist, at muscarinic acetylcholine M2 receptors. J Pharmacol Exp Ther 1997; 282: 278–285
   Google Scholar
• Christopoulos A, Kenakin T. G protein-coupled receptor allosterism and complexing. Pharmacol Rev 2002; 54: 323–374
   PubMed Web of Science ®Google Scholar
• Birdsall N J, Lazareno S, Popham A, Saldanha J. Multiple allosteric sites on muscarinic receptors. Life Sci 2001; 68: 2517–2524
   Google Scholar
• May L T, Christopoulos A. Allosteric modulators of G-protein-coupled receptors. Curr Opin Pharmacol 2003; 3: 551–556
   PubMed Web of Science ®Google Scholar
• Maass A, Kostenis E, Mohr K. Potentiation by alcuronium of the antimuscarinic effect of N-methylscopolamine in guinea pig left atria. Eur J Pharmacol 1995; 272: 103–106
   Google Scholar
• Birdsall N J, Farries T, Gharagozloo P, Kobayashi S, Lazareno S, Sugimoto M. Subtype-selective positive cooperative interactions between brucine analogs and acetylcholine at muscarinic receptors: functional studies. Mol Pharmacol 1999; 55: 778–786
   Google Scholar
• Birdsall N J, Farries T, Gharagozloo P, Kobayashi S, Kuonen D, Lazareno S, et al. Selective allosteric enhancement of the binding and actions of acetylcholine at muscarinic receptor subtypes. Life Sci 1997; 60: 1047–1052
   PubMed Web of Science ®Google Scholar
• Jakubik J, Bacakova L, El-Fakahany E E, Tucek S. Positive cooperativity of acetylcholine and other agonists with allosteric ligands on muscarinic acetylcholine receptors. Mol Pharmacol 1997; 52: 172–179
   PubMed Web of Science ®Google Scholar
• Matsui S, Fu M L, Hayase M, Katsuda S, Yamaguchi N, Teraoka K, et al. Beneficial effect of muscarinic-2 antagonist on dilated cardiomyopathy induced by autoimmune mechanism against muscarinic-2 receptor. J Cardiovasc Pharmacol 2001; 38: S43–49
   Google Scholar